miR-135b inhibits tumour metastasis in prostate cancer by targeting STAT6

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• MicroRNAs (miRNAs) are key regulators of cellular functions and implicated in cancer progression.
• Previous studies indicated miR-135b downregulation in prostate cancer (PCa), but its role in metastasis was unclear.
• Understanding miRNA regulation in PCa is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role and molecular mechanism of miR-135b in prostate cancer (PCa) metastasis.
• To identify the downstream targets of miR-135b in PCa cells.
• To explore the therapeutic potential of miR-135b in PCa.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (RT-qPCR) to measure miR-135b expression in PCa tissues.
• Luciferase activity and Western blot assays to identify and validate STAT6 as a miR-135b target.
• In vitro cell migration and invasion assays to assess the functional impact of miR-135b and STAT6.

Main Results:

• miR-135b was significantly downregulated in PCa tissues compared to non-cancerous tissues.
• miR-135b expression correlated with PCa pathological stage and prostate-specific antigen (PSA) levels.
• Signal transducer and activator of transcription 6 (STAT6) was identified as a direct target of miR-135b.
• Overexpression of miR-135b reduced STAT6 expression and inhibited PCa cell migration and invasion.

Conclusions:

• miR-135b acts as a tumor suppressor in prostate cancer by inhibiting metastasis.
• The miR-135b/STAT6 axis represents a novel regulatory pathway in PCa progression.
• Targeting miR-135b or STAT6 may offer a potential therapeutic strategy for prostate cancer treatment.